Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Regeneron is presented as the preferred 2026 investment after FY2025 revenue rose 1% to $14.3B and net income reached $4.5B, while its latest quarter reportedly delivered record sales across Dupixent, EYLEA HD and Libtayo and a wide earnings beat. Novo Nordisk generated substantially larger FY2025 revenue of $47.7B (+6.4%) and $15.8B of net income, but faces GLP-1 pricing pressure, potential U.S. coverage reductions and increased competition from Eli Lilly. Regeneron has stronger balance-sheet liquidity, with 0.1x debt-to-equity and a 4.1x current ratio versus Novo's 0.7x and 0.8x, although it carries product, distributor and partner concentration risks.

Analysis

REGN’s apparent diversification is less complete than the narrative suggests: Dupixent economics are shared with SNY, while EYLEA’s conversion to HD must outrun both biosimilar erosion and incremental rebate pressure to preserve franchise profitability. The key 1-3 month catalyst is whether management can demonstrate that EYLEA HD mix expansion is producing stable net revenue per patient rather than merely shifting volume within the franchise. A clean beat driven by collaboration revenue alone should not command a higher multiple; product-demand guidance and EYLEA net-price commentary matter more.

NVO’s lower earnings multiple already discounts a meaningful deceleration, creating an asymmetrical setup versus the broadly accepted GLP-1 pricing-risk narrative. The underappreciated variable is not headline competition, but the ability of oral obesity treatment to expand the treated population beyond injectable users; that would reduce the relevance of supply constraints and could improve marketing efficiency. Conversely, any U.S. reimbursement restriction or formulary concession that lowers realized net price faster than volume growth would validate a structurally lower margin regime over the next 6-18 months.

The cleaner relative-value expression is selective rather than a blanket REGN-over-NVO call. REGN has nearer-term execution catalysts but carries an EYLEA franchise-reset risk; NVO has more policy and competitive uncertainty but materially greater embedded skepticism. Consensus may be over-crediting REGN’s recent operating momentum as durable and under-crediting NVO’s ability to monetize a larger addressable market through oral adoption.

Key Decisions for Investors

• Initiate a modest long REGN position only ahead of the next earnings update if EYLEA HD prescription/share data remain favorable; target 10-15% upside on sustained product-growth guidance, with a stop/review trigger on evidence of accelerating EYLEA net-price declines or a cut to ophthalmology outlook.
• Run a 3-6 month value pair: long NVO / short REGN in equal dollar amounts after any post-earnings REGN strength. The thesis is valuation convergence if REGN’s EYLEA transition disappoints while NVO demonstrates oral-obesity volume traction; exit if NVO lowers full-year operating-margin guidance or REGN raises core-product guidance excluding collaboration revenue.
• Monitor U.S. payer decisions, Medicaid coverage changes, and realized GLP-1 net-price disclosures as the principal NVO catalyst/risk set. Do not add aggressively before confirmation that prescription growth is offsetting price concessions.
• Avoid treating TLX collaboration news as a material REGN earnings driver until deal economics, development costs, and approval timelines are disclosed; use it as a pipeline-optionality watch item rather than a standalone trade catalyst.